

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16. (Canceled)

17. (Currently Amended) A method for treating chronic lymphocytic leukemia (CLL) in a mammalian subject comprising administering to said subject an effective amount of an isolated monoclonal antibody that specifically binds to a polypeptide comprising the sequence set forth in SEQ ID NO: 4 wherein said monoclonal antibody has a binding constant for SEQ ID NO:4 that exceeds  $10^3$  L/mol, and does not react detectably with polypeptides unrelated to SEQ ID NO: 4.

18-20. (Canceled)

21. (Previously Presented) The method of claim 17, wherein said antibody is a humanized antibody.

22. (Previously Presented) The method of claim 17, wherein said antibody is a chimeric antibody.

23. (Previously Presented) The method of claim 17, wherein said antibody is a Fab fragment.

24. (Currently Amended) The method of claim 17, wherein said antibody is a Fv ~~fragment~~ fragment.

25. (Previously Presented) The method of claim 17, wherein said antibody is a scFv.

26. (Previously Presented) The method of claim 17, wherein said antibody further comprises a therapeutic moiety.

27. (Previously Presented) The method of claim 26, wherein the therapeutic moiety is a radionuclide.
28. (Previously Presented) The method of claim 27, wherein the radionuclide is a member selected from the group consisting of:  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{186}\text{Re}$ ,  $^{211}\text{At}$ , and  $^{212}\text{Bi}$ .
- 29-31. (Canceled)
32. (Previously Presented) The method of claim 27, wherein the mammalian subject is a human.
33. (Previously Presented) The method of claim 17, wherein administration is intravenous.
- 34-53. (Canceled)
54. (Previously Presented) The method of claim 17, wherein the monoclonal antibody is not a bi-specific antibody.